Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03319849
Recruitment Status : Recruiting
First Posted : October 24, 2017
Last Update Posted : March 22, 2019
Sponsor:
Information provided by (Responsible Party):
Neurotech Pharmaceuticals

Brief Summary:
This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the Renexus® implants in participants with macular telangiectasia type 2.

Condition or disease Intervention/treatment Phase
Macular Telangiectasia Type 2 Combination Product: Renexus® Procedure: Sham Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 112 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2
Actual Study Start Date : February 6, 2018
Estimated Primary Completion Date : March 31, 2021
Estimated Study Completion Date : March 31, 2021

Arm Intervention/treatment
Experimental: Renexus® Combination Product: Renexus®
Surgery to receive one Renexus® device implant.

Sham Comparator: Sham Procedure: Sham
Non-penetrating sham procedure to mimic implant procedure.




Primary Outcome Measures :
  1. Mean Change in Ellipsoid Zone (EZ) [ Time Frame: Baseline through 24 months. ]
    Mean change in EZ as measured by en face imaging by Spectral-Domain Optical Coherence Tomography (SD-OCT) in the study eye.


Secondary Outcome Measures :
  1. Central Macular Thickness [ Time Frame: Baseline through 24 months. ]
    Renexus® compared to sham relative to mean change in central macular thickness.

  2. Proportion of Eyes with >35% Increase in EZ Break Area [ Time Frame: From baseline at month 24. ]
    Renexus ® compared to sham relative to proportion of eyes with >35% increase in EZ break area.

  3. Mean Change in Aggregate Sensitivity of Microperimetry [ Time Frame: Baseline through 24 months. ]
    Renexus ® compared to sham relative to mean change in aggregate sensitivity of microperimetry within the EZ line break area.

  4. Mean Change in Reading Speed [ Time Frame: Baseline through 24 months. ]
    Renexus® compared to sham relative to mean change in reading speed assessed using Internal Reading Speed Texts (IReST) cards.

  5. National Eye Institute-Visual Function Questionnaire (NEI-VFQ) [ Time Frame: Baseline through 24 months. ]
    Renexus® compared to sham relative to mean change in the NEI-VFQ near activities subscale score.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Participant must have at least one study eye with a positive diagnosis of MacTel Type 2
  • Participant must have an Inner Segment - Outer Segment Junction Line (IS/OS) Photo Receptor (PR) break in the study eye(s) and en face EZ (area of IS/OS loss) as measured by spectral-domain optical coherence tomography (SDOCT) between 0.16 mm^2 and 2.00 mm^2
  • Participant's best corrected visual acuity is 54 letter score or better (20/80 or better) as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart

Key Exclusion Criteria:

  • Participant received intravitreal steroid therapy for non-neovascular MacTel within the last 3 months
  • Participant has ever received intravitreal anti-vascular endothelial growth factor (VEGF) therapy in the study eye or has, within the past 3 months, received intravitreal anti-VEGF in the fellow eye
  • Participant has evidence of ocular disease other than MacTel that, in the judgment of the examining physician, may confound the diagnosis, procedures or outcome of the study
  • Participant was a study participant in any other clinical trial of an intervention (drug or device) within the last 6 months
  • Participant is pregnant or breastfeeding
  • Participant has a chronic requirement (eg ≥ 4 weeks at a time) for ocular medications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03319849


Contacts
Layout table for location contacts
Contact: Kenneth J. Mandell, MD, PhD 678-427-2334 k.mandell@neurotechusa.com

  Show 20 Study Locations
Sponsors and Collaborators
Neurotech Pharmaceuticals
Investigators
Layout table for investigator information
Study Chair: Kenneth J. Mandell, MD, PhD Neurotech Pharmaceuticals, Inc.

Layout table for additonal information
Responsible Party: Neurotech Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03319849     History of Changes
Other Study ID Numbers: NTMT-03-B
First Posted: October 24, 2017    Key Record Dates
Last Update Posted: March 22, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No

Keywords provided by Neurotech Pharmaceuticals:
Ciliary Neurotrophic Factor (CNTF)
Macular Telangiectasia (MacTel)

Additional relevant MeSH terms:
Layout table for MeSH terms
Telangiectasis
Vascular Diseases
Cardiovascular Diseases